{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 76 of 169', 'Test dummy transmissions will be undertaken prior to trial conduct to ensure that', 'transmissions can be made and that date and time settings are correctly set.', 'The collection and transmission of ECG data will be described in a separate ECG manual.', '10.4.4 Pregnancy test', 'A serum pregnancy test must be taken at the screening visit in female subjects of', 'child-bearing potential as described in the SoP in Section 4.', 'A urine pregnancy test (human chorionic gonadotropin; dipstick) must be performed at the', 'trial site at baseline prior to randomisation in female subjects of child-bearing potential. The', 'test must be repeated every 4 weeks as shown in the SoP in Section 4.', 'Note that pregnant subjects must discontinue IMP immediately (Section 9.8.1).', '10.4.5 Laboratory testing', 'The following safety samples will be analysed by a central laboratory: chemistry,', 'haematology, serology, and serum pregnancy (Panel 13). Urine samples will be tested at the', 'trial site with a dipstick; if abnormal, a urine sample will be sent to the central laboratory for', 'further analysis.', 'A laboratory manual will be provided to the sites that specifies the procedures for collection,', 'processing, storage, and shipment of samples, as well as laboratory contact information', 'specific to this trial.', 'Samples for laboratory testing will be collected according to the SoP (Section 4).', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 77 of 169', 'Panel 13 Central laboratory testing', 'Chemistry', 'Haematology', 'Sodium', 'Erythrocytes', 'Potassium', 'Hematocrit', 'Creatinine', 'Hemoglobin', 'Urea nitrogen', 'Erythrocyte mean corpuscular volume', 'Calcium', 'Erythrocyte mean corpuscular haemoglobin', 'Alkaline phosphatase', 'concentration', 'Aspartate aminotransferase', 'Leukocytes', 'Alanine aminotransferase', 'Neutrophils, neutrophils/total cells', 'Gamma glutamyl transferase', 'Lymphocytes, lymphocytes/total cells', 'Bilirubin\u00b9', 'Monocytes, monocytes/total cells', 'Lactate dehydrogenase', 'Eosinophils, eosinophils/total cells', 'Cholesterol', 'Basophils, basophils/total cells', 'LDL cholesterol', 'Thrombocytes', 'HDL cholesterol', 'Serology', 'Triglycerides', 'Hepatitis B virus surface antigen4', 'Glucose (non-fasting)', 'Hepatitis B virus surface antibody4', 'Albumin', 'Hepatitis B virus core antibody4', 'Protein', 'Hepatitis C virus antibody4', 'Tryptase\u00b2', 'HIV-1 antibody4', 'HIV-2 antibody4', 'Immunoglobulin E5', 'Urinalysis\u00b3', 'Serum pregnancy test (females only)4', 'Protein', 'Choriogonadotropin beta', 'Glucose', 'Ketones', 'Occult blood', 'Leukocytes', 'Nitrite', '1)', 'If bilirubin is above upper limit of normal, direct and indirect bilirubin will also be measured.', '2) Only measured in case of suspected anaphylaxis (Section 9.2).', '3)', 'Urine samples will be tested at the trial site (dipstick). In case of abnormal dipstick results, a urine sample', 'will be sent to the central laboratory for microscopic examination (leukocytes, erythrocytes, and casts).', '4) Measured at screening only.', '5) Not measured at screening.', 'HDL, high density lipoprotein; LDL, low density lipoprotein.', \"The investigator must evaluate all results outside the reference range ('clinically significant'\", 'or \"not clinically significant\\') and sign and date. The signed and dated version will be filed', \"with the investigator's trial documentation. Clinically significant abnormal tests must be\", 'repeated to confirm the abnormality.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 78 of 169', 'The central laboratory will provide results in conventional units to trial sites in the US and in', 'SI', 'units to trial sites in Europe and Asia; results that are transferred to the trial database will', 'be in conventional and SI units.', 'Handling, storage, destruction and shipment instructions are provided in a separate laboratory', 'manual.', 'If a screening laboratory result is abnormal and of clinical significance, it will be at the', \"investigator's discretion to decide if the subject should be enrolled into the trial (respecting\", 'exclusion criteria no. 26,27, and 28).', '10.4.6 Pharmacokinetic assessments', 'Blood samples for PK assessments must be collected at the time points specified in the SoP', '(Section 4). Note that at Week 15, a blood sample for PK will be drawn but no assessments', 'that require trial personnel will be performed.', 'Collection, handling and shipment instructions for PK blood samples are provided in a', 'laboratory manual.', 'Serum samples for determination of tralokinumab concentrations will be analysed by a', 'laboratory using a validated bioanalytical method. Details of the analytical method used will', 'be described in the bioanalytical report.', 'Samples will be retained for as long as the quality of the material permits evaluation but for', 'no longer than 12 months after completion of the clinical trial report (CTR).', '10.4.7 Anti-drug antibodies measurements', 'Blood samples will be collected for determination of anti-tralokinumab antibody levels at', 'pre-determined time points according to the SoP (Section 4).', 'Collection, handling and shipment instructions for ADA blood samples are provided in a', 'separate laboratory manual.', 'Serum samples for determination of presence or absence ADA will be analysed by a', 'laboratory using a validated bioanalytical method. A tiered testing scheme will be employed,', 'with the first step being screening. Samples found positive in the screening step will be tested', 'in the confirmatory step. Samples confirmed positive for ADA in the confirmatory step will', 'undergo ADA endpoint titre determination and will be analysed for the presence of', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}